TY - JOUR
T1 - Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target
AU - Wei, Jun
AU - Marisetty, Anantha
AU - Schrand, Brett
AU - Gabrusiewicz, Konrad
AU - Hashimoto, Yuuri
AU - Ott, Martina
AU - Grami, Zacharia
AU - Kong, Ling Yuan
AU - Ling, Xiaoyang
AU - Caruso, Hillary
AU - Zhou, Shouhao
AU - Wang, Y. Alan
AU - Fuller, Gregory N.
AU - Huse, Jason
AU - Gilboa, Eli
AU - Kang, Nannan
AU - Huang, Xingxu
AU - Verhaak, Roel
AU - Li, Shulin
AU - Heimberger, Amy B.
N1 - Publisher Copyright:
© 2019 American Society for Clinical Investigation. All rights reserved.
PY - 2019/1/2
Y1 - 2019/1/2
N2 - Glioblastoma is highly enriched with macrophages, and osteopontin (OPN) expression levels correlate with glioma grade and the degree of macrophage infiltration; thus, we studied whether OPN plays a crucial role in immune modulation. Quantitative PCR, immunoblotting, and ELISA were used to determine OPN expression. Knockdown of OPN was achieved using complementary siRNA, shRNA, and CRISPR/Cas9 techniques, followed by a series of in vitro functional migration and immunological assays. OPN gene-deficient mice were used to examine the roles of non-tumor-derived OPN on survival of mice harboring intracranial gliomas. Patients with mesenchymal glioblastoma multiforme (GBM) show high OPN expression, a negative survival prognosticator. OPN is a potent chemokine for macrophages, and its blockade significantly impaired the ability of glioma cells to recruit macrophages. Integrin αvβ5 (ITGαvβ5) is highly expressed on glioblastoma-infiltrating macrophages and constitutes a major OPN receptor. OPN maintains the M2 macrophage gene signature and phenotype. Both tumor-derived and host-derived OPN were critical for glioma development. OPN deficiency in either innate immune or glioma cells resulted in a marked reduction in M2 macrophages and elevated T cell effector activity infiltrating the glioma. Furthermore, OPN deficiency in the glioma cells sensitized them to direct CD8+ T cell cytotoxicity. Systemic administration in mice of 4-1BB-OPN bispecific aptamers was efficacious, increasing median survival time by 68% (P < 0.05). OPN is thus an important chemokine for recruiting macrophages to glioblastoma, mediates crosstalk between tumor cells and the innate immune system, and has the potential to be exploited as a therapeutic target.
AB - Glioblastoma is highly enriched with macrophages, and osteopontin (OPN) expression levels correlate with glioma grade and the degree of macrophage infiltration; thus, we studied whether OPN plays a crucial role in immune modulation. Quantitative PCR, immunoblotting, and ELISA were used to determine OPN expression. Knockdown of OPN was achieved using complementary siRNA, shRNA, and CRISPR/Cas9 techniques, followed by a series of in vitro functional migration and immunological assays. OPN gene-deficient mice were used to examine the roles of non-tumor-derived OPN on survival of mice harboring intracranial gliomas. Patients with mesenchymal glioblastoma multiforme (GBM) show high OPN expression, a negative survival prognosticator. OPN is a potent chemokine for macrophages, and its blockade significantly impaired the ability of glioma cells to recruit macrophages. Integrin αvβ5 (ITGαvβ5) is highly expressed on glioblastoma-infiltrating macrophages and constitutes a major OPN receptor. OPN maintains the M2 macrophage gene signature and phenotype. Both tumor-derived and host-derived OPN were critical for glioma development. OPN deficiency in either innate immune or glioma cells resulted in a marked reduction in M2 macrophages and elevated T cell effector activity infiltrating the glioma. Furthermore, OPN deficiency in the glioma cells sensitized them to direct CD8+ T cell cytotoxicity. Systemic administration in mice of 4-1BB-OPN bispecific aptamers was efficacious, increasing median survival time by 68% (P < 0.05). OPN is thus an important chemokine for recruiting macrophages to glioblastoma, mediates crosstalk between tumor cells and the innate immune system, and has the potential to be exploited as a therapeutic target.
UR - http://www.scopus.com/inward/record.url?scp=85059426859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059426859&partnerID=8YFLogxK
U2 - 10.1172/JCI121266
DO - 10.1172/JCI121266
M3 - Article
C2 - 30307407
AN - SCOPUS:85059426859
SN - 0021-9738
VL - 129
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 1
M1 - CI121266
ER -